Gene transfer to skeletal muscle using herpes simplex virus-based vectors.

Area of Science:

• Molecular Biology
• Gene Therapy
• Virology

Background:

• Herpes simplex virus type 1 (HSV-1) vectors are explored for gene delivery due to their large DNA carrying capacity and ability to transduce muscle cells.
• First-generation HSV vectors exhibit cytotoxicity, limiting long-term transgene expression.
• Second-generation HSV-1 vectors with mutations in immediate early genes show reduced cytotoxicity and improved transgene expression duration.

Purpose of the Study:

• To describe a novel gene delivery method utilizing second-generation HSV-1 vectors.
• To enable efficient transduction of normal mouse muscle cells both in vitro and in vivo.
• To provide detailed protocols for muscle cell isolation, transduction, and efficiency evaluation.

Main Methods:

• Utilized second-generation HSV-1 vectors defective for multiple immediate early genes (ICP4, ICP22, ICP27).
• Developed protocols for isolating mouse muscle cells.
• Performed in vitro and in vivo transduction experiments.
• Assessed transduction efficiency using beta-galactosidase (beta-gal) via histology and the ONPG assay.

Main Results:

• Second-generation HSV-1 vectors demonstrated reduced cytotoxicity compared to first-generation vectors.
• Efficient transduction of myoblasts, myotubes, and immature myofibers was achieved.
• The described method allows for successful gene delivery to mouse muscle cells in vitro and in vivo.

Conclusions:

• Second-generation HSV-1 vectors represent a promising tool for gene delivery to muscle tissue with improved safety profiles.
• The presented methodology facilitates the study and application of HSV-1 based gene therapy in muscle cells.
• This approach holds potential for advancing gene therapy strategies targeting muscle diseases.